Bradbury, M.; Savard, M.-F.; Vandermeer, L.; Clemons, L.; Pond, G.; Hilton, J.; Clemons, M.; McGee, S.
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Curr. Oncol. 2023, 30, 10477-10487.
https://doi.org/10.3390/curroncol30120763
AMA Style
Bradbury M, Savard M-F, Vandermeer L, Clemons L, Pond G, Hilton J, Clemons M, McGee S.
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current Oncology. 2023; 30(12):10477-10487.
https://doi.org/10.3390/curroncol30120763
Chicago/Turabian Style
Bradbury, Michelle, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark Clemons, and Sharon McGee.
2023. "Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective" Current Oncology 30, no. 12: 10477-10487.
https://doi.org/10.3390/curroncol30120763
APA Style
Bradbury, M., Savard, M.-F., Vandermeer, L., Clemons, L., Pond, G., Hilton, J., Clemons, M., & McGee, S.
(2023). Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. Current Oncology, 30(12), 10477-10487.
https://doi.org/10.3390/curroncol30120763
